You are here
Home > Medical Calculator > Mayo Score for Assessment of Ulcerative Colitis – Updated

Mayo Scoring System for Assessment of Ulcerative Colitis

Which one should you choose?  "The partial Mayo score performed as well as the full Mayo score to identify patient perceived clinical response. " 1  The Partial Mayo clinic score can easily be performed at the bedside for not only initial assessment, but also follow-up visits to assess the impact of clinical interventions.
Select Mayo Scoring system preference:  
Full Mayo Score (Includes endoscopic findings)

Partial Mayo Score (eliminates endoscopy)
1. Stool frequency (per day): 1
 
2. Rectal bleeding  (indicate the most severe bleeding of the day):

[Assigning a score of 3 requires patients to have >/=50% of bowel movement accompanied by visible blood and 1+ bowel movement with blood alone.]2
3. Mucosal appearance at endoscopy

[Ignore if you selected Partial Mayo Score]
4. Physician’s Global Assessment:*

[*The physician’s Global Assessment acknowledges the sub scores, the daily record of abdominal discomfort and functional assessment and other observations such as physical findings, and the patient’s performance status.]2

Background Info

Scoring:

Stool Frequency
0 = Normal
1 = 1-2 stools/day more than normal
2 = 3-4 stools/day more thannormal
3 = 5 or more stools/day than normal

Rectal bleeding
0 = None
1 = Visible blood with stool less than half the time
2 = Visible blood with stool half of the time or more
3 = Passing blood alone

Mucosal appearance at endoscopy
0 = Normal or inactive disease
1 = Mild disease (erythema, decreased vascular pattern, mild friability
2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions)
3 = Severe disease (spontaneous bleeding, ulceration)

Physician rating of disease activity
0 = Normal
1 = Mild
2 = Moderate
3 = Severe


Assessment based on Scoring:
Full Mayo Index Score:
-----------------------------------------
Maximum score: 12.  Higher scores indicate more severe disease (Ulcerative colitis).  A critical component of this score are the endoscopic findings.  Patient's with lower scores but with an endoscopic score of 2 or greater are considered more severe regardless of the final score.


Partial Mayo Index Score
Mucosal appearance at endoscopy is not included.
-----------------------------------------
Remission
: 0-1 [Remission defined as patient assessment of disease activity as perfect or very good (minimal symptoms).]3
Mild Disease: 2-4
Moderate Disease: 5-6
Severe Disease: 7-9


References

  1. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353 (23): 2462-2476.
    https://www.ncbi.nlm.nih.gov/pubmed/16339095


  2. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalcylic acid therapy for mildly to moderately active ulcerative colitis. N Eng J Med 1987; 317 (26): 1625-1629.
    https://www.ncbi.nlm.nih.gov/pubmed/3317057


  3. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008; 14 (12): 1660-1666.
    https://www.ncbi.nlm.nih.gov/pubmed/18623174



Gastroenterology and related calculators


Calculators / Tools

ABIC score – Stratification of risk of death in alcoholic hepatitis (AH)
Alcoholic Hepatitis Histological Score (AHHS)- Prognostic Stratification of Alcoholic Hepatitis
Child-Turcotte-Pugh Score -chronic liver disease - used to assess the prognosis of chronic liver disease, mainly cirrhosis. Although it was originally used to predict mortality during surgery, it is now used to determine the prognosis, as well as the required strength of treatment and the necessity of liver transplantation.
Crohn's Disease Activity Index (CDAI) - The CDAI is an important research tool for quantifying symptoms as well as determining the impact of drug therapy on overall symptoms.
Forrest classification - Risk stratification of upper gastrointestinal hemorrhage -UGIB
Glasgow alcoholic hepatitis score (GAHS) predicts survival from alcoholic hepatitis with respect to individual Glasgow alcoholic hepatitis score (GAHS) values
Glasgow-Blatchford bleeding score (GBS) - Screening tool for acute upper gastrointestinal bleeding (UGIB)  
Harvey-Bradshaw Index - useful tool for assessing the degree of illness (activity) in patient's with Crohn's disease
Irritable Bowel Syndrome (IBS) treatment options
Lille Model Scoring in Severe Alcoholic Hepatitis - helps to identify patients 'early' with severe alcoholic hepatitis that are likely to respond to steroid therapy or who will require alternative treatment options.
Mayo Scoring System for Assessment of Ulcerative Colitis
MELD Score (Model For End-Stage Liver Disease) -useful tool in predicting the probability of death from liver disease and how urgently an individual needs a liver transplant in the next three months.
MELD-Na Score (Model For End-Stage Liver Disease) -United Network for Organ Sharing proposed that MELD-Na score (an extension of MELD) may better rank candidates based on their risk of pre-transplant mortality and is projected to save 50-60 lives total per year.
Modified Maddrey's discriminant function (mDF) - (Score) is a predictive statistical model useful for evaluating the severity and prognosis in alcoholic hepatitis
Ransons Criteria mortality risk for acute pancreatitis- clinical prediction rule for predicting the prognosis and mortality risk of acute pancreatitis.
Rockall score for the evaluation of upper gastrointestinal bleeding - based on clinical criteria including age, shock and presence of other comorbidities. The scoring system helps evaluate patients at risk of re-bleeding or death following acute upper gastrointestinal bleeding
Rome iii criteria for IBS
Rome IV diagnostic criteria -Irritable Bowel Syndrome
Stool Osmotic Gap- Secretory vs Osmotic diarrhea
gastroenterology

Disclaimer

The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer